NAP-226-90

NAP‑226‑90 is a small molecule metabolite of rivastigmine, formed by hydrolysis. It is classified as a 1-hydroxy‑4-unsubstituted benzenoid and is also known as an acetylcholinesterase inhibitor. NAP‑226‑90 has been studied primarily in the context of its role as a metabolite in pharmacokinetic and mechanistic studies of rivastigmine, which is used for symptomatic treatment of Alzheimer's disease. The compound itself has not been approved for therapeutic use and remains experimental[1][2][7]. Its mechanism involves inhibition of acetylcholinesterase, similar to its parent drug[7].

Other names

(-)-3-((1S)-1-(Dimethylamino)ethyl)phenol3-((1S)-1-(Dimethylamino)ethyl)phenol(S)-3-(1-(dimethylamino)ethyl)phenol3-[(1S)-1-(dimethylamino)ethyl]phenolPhenol, 3-[1-(dimethylamino)ethyl]-Rivastigmine specified impurity A [EP]Rivastigmine hydrogen tartrate specified impurity A [EP]RIVASTIGMINE IMPURITY A [EP IMPURITY]RIVASTIGMINE HYDROGEN TARTRATE IMPURITY A [EP IMPURITY]RIVASTIGMINE IMPURITY A (EP IMPURITY)Rivastigmine tartrate impurity, phenol impurity-(USP)